Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis

References

• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182–205
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417–29
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599–603
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603–6
   PubMed Web of Science ®Google Scholar
• Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925–8
   PubMed Web of Science ®Google Scholar
• Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001; 276: 4812–8
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869–72
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Chen FF, Muto A, Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 2001; 276: 2551–4
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 2002; 5: 76–80
   PubMed Web of Science ®Google Scholar
• Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem 2002; 277: 41701–5
   PubMed Web of Science ®Google Scholar
• Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 2003; 52: 840–6
   PubMed Web of Science ®Google Scholar
• Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124: 1001–9
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993–1000
   PubMed Web of Science ®Google Scholar
• Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371–82
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509–12
   PubMed Web of Science ®Google Scholar
• Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function?. Immunity 2005; 22: 661–7
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800–8
   PubMed Web of Science ®Google Scholar
• Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1ß processing. Science 2005; 307: 734–8
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731–4
   PubMed Web of Science ®Google Scholar
• Kelsall B. Getting to the guts of NOD2. Nat Med 2005; 11: 383–4
   PubMed Web of Science ®Google Scholar
• Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype–phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845–57
   PubMed Web of Science ®Google Scholar
• Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124: 521–36
   PubMed Web of Science ®Google Scholar
• Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679–88
   PubMed Web of Science ®Google Scholar
• Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854–66
   PubMed Web of Science ®Google Scholar
• Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867–74
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99: 2393–404
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106–11
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Brand S, Staudinger T, Pfennig S, Hofbauer K, Seiderer J, et al. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics 2006; 58: 99–106
   PubMed Web of Science ®Google Scholar
• Gasche C, Schölmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8–15
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, Tulassay Z, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype–genotype correlations. World J Gastroenterol 2005; 11: 1489–95
   PubMed Web of Science ®Google Scholar
• Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, et al. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian group of inflammatory bowel disease study. Dig Liver Dis 2004; 36: 121–4
   PubMedGoogle Scholar
• Vavassori P, Borgiani P, Biancone L, D'Apice MR, Blanco Gdel V, Vallo L, et al. CARD15 mutation analysis in an Italian population: Leu107fsincC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease. Inflamm Bowel Dis 2004; 10: 116–21
   PubMed Web of Science ®Google Scholar
• Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease: an IG-IBD study. Am J Gastroenterol 2005; 100: 84–92
   PubMed Web of Science ®Google Scholar
• Radlmayr M, Török HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122: 2091–2
   PubMed Web of Science ®Google Scholar
• Török HP, Glas J, Lohse P, Folwaczny C. Alterations of the CARD15/NOD2 gene and the impact on management and treatment of Crohn's disease patients. Dig Dis 2003; 21: 339–45
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723–9
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003; 17: 131–7
   PubMed Web of Science ®Google Scholar
• Hommes D, Baert F, van Assche G, Caenepeel F, Vergauwe P, Tuynman H, et al. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005; 129: 371
   Google Scholar
• van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, Ahmad T, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005; 365: 1794–6
   PubMed Web of Science ®Google Scholar
• Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, Naber TH, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052–9
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 2004; 53: 1658–64
   PubMed Web of Science ®Google Scholar
• Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003; 125: 47–57
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731–4
   PubMed Web of Science ®Google Scholar
• Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11: 645–52
   PubMed Web of Science ®Google Scholar
• Török HP, Glas J, Tonenchi L, Lohse P, Muller-Myhsok B, Limbersky O, et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 2005; 54: 1421–7
   PubMed Web of Science ®Google Scholar
• Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol 2006; 101: 99–106
   PubMed Web of Science ®Google Scholar
• Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 14;307: 254–8
   Web of Science ®Google Scholar
• Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777–82
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244–50
   PubMed Web of Science ®Google Scholar
• Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al. Genetic basis for increased intestinal permeability in CARD15 families with Crohn's disease: role of 3020insC mutation?. Gut 2006; 55: 342–7
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123–8
   PubMed Web of Science ®Google Scholar
• Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424–31
   PubMed Web of Science ®Google Scholar
• Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552–7
   PubMed Web of Science ®Google Scholar
• Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004; 10: 521–8
   PubMed Web of Science ®Google Scholar